Effect of serum and C‐apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase

No abstract is available for this paper.

• Publication year

  1976

• Venue

  FEBS Letters

• Publication date

  1976-06-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0014-5793(76)80145-7PMID 182536
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heterogeneity of salt‐resistant lipase from human postheparin plasma

  1975cited by this paper
• The hydrolytic and transacylation activity of the phospholipase A1 purified from human post-heparin plasma.

  1975cited by this paper
• Purification and characterization of lipoprotein lipase from pig myocardium.

  1975cited by this paper
• Purification from human plasma of a heparin-released lipase with activity against triglyceride and phospholipids.

  1975cited by this paper
• Activation of highly purified lipoprotein lipase from bovine milk.

  1975cited by this paper
• An in vitro model for the catabolism of rat chylomicrons.

  1975cited by this paper
• LIVER AND EXTRAHEPATIC CONTRIBUTIONS TO POSTHEPARIN SERUM LIPASE ACTIVITY OF THE RAT

  1974cited by this paper
• Purification and characterization of lipoprotein lipase from pig adipose tissue.

  1974cited by this paper
• Evidence for the hepatic origin of a canine post‐heparin plasma triglyceride lipase

  1974cited by this paper
• A comparative study of post-heparin lipolytic activity and a purified human plasma triacylglycerol lipase.

  1974cited by this paper
• Blood lipids and lipoproteins; quantitation, composition and metabolism

  1973cited by this paper
• Characterization, subcellular localization, and partial purification of a heparin-released triglyceride lipase from rat liver.

  1973cited by this paper
• Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man.

  1973cited by this paper
• Lipoprotein lipase from heart and liver: an immunological study.

  1973cited by this paper
• On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein.

  1973cited by this paper
• Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources.

  1973cited by this paper
• Very low density lipoprotein "remnant" particles: uptake by aortic smooth muscle cells in culture.

  1973cited by this paper
• Purification of a human post‐heparin plasma triglyceride lipase

  1972cited by this paper
• Further characterisation of lipoprotein lipase and hepatic post-heparin lipase from rat plasma.

  1972cited by this paper
• Comparison of the triglyceride lipase of liver, adipose tissue, and postheparin plasma.

  1972cited by this paper
• Apoliproproteins and lipoproteins.

  1971cited by this paper
• Correction of COOH-terminal amino acids of human plasma very low density apolipoproteins.

  1971cited by this paper
• Quantitative studies of the metabolism of chylomicron triglycerides and cholesterol by liver and extrahepatic tissues of sheep and dogs.

  1971cited by this paper
• Formation of cholesteryl ester-rich particulate lipid during metabolism of chylomicrons.

  1970cited by this paper
• Studies of the proteins in human plasma very low density lipoproteins.

  1969cited by this paper
• The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

  1955cited by this paper

• Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.

  2026cites this paper
• Lipid-Lowering RNA Therapeutics for Atherosclerotic Cardiovascular Disease Prevention: A State−of−the−Art Review

  2025cites this paper
• Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen.

  2024cites this paper
• A Combined Fertility and Developmental Toxicity Study with an Antisense Oligonucleotide Targeting Murine Apolipoprotein C-III mRNA in Mice

  2024cites this paper
• The Emerging Potential of Apolipoprotein C-III Inhibition for ASCVD Prevention: A State-of-the-Art Review

  2024cites this paper
• Hypertriglyceridemia: diagnostic issues, therapeutic strategies

  2024cites this paper
• FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet

  2024cites this paper
• Posicionamento Brasileiro sobre Síndrome da Quilomicronemia Familiar – 2023

  2023cites this paper
• Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids

  2023cites this paper
• Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention

  2022cites this paper
• Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy.

  2022cites this paper
• Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review

  2022cites this paper
• Comprehensive (apo)lipoprotein profiling in patients with genetic hypertriglyceridemia using LC-MS and NMR spectroscopy.

  2022cites this paper
• Human apolipoprotein C1 transgenesis reduces atherogenesis in hypercholesterolemic rabbits.

  2021cites this paper
• The Importance of Lipoprotein Lipase Regulation in Atherosclerosis

  2021cites this paper
• Lowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements

  2021cites this paper
• Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models

  2020cites this paper
• The forkhead box O family in insulin action and lipid metabolism

  2020cites this paper
• Профилирование аполипопротеинов как вариант персонифицированного подхода к диа-гностике и коррекции дислипидемий

  2020cites this paper
• Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference[S]

  2019cites this paper
• Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia

  2019cites this paper
• Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome

  2018cites this paper
• Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials.

  2018cites this paper
• Dietary unsaturated fat improves high density lipoprotein function: opposing roles of apoE and apoCIII

  2018cites this paper
• Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management.

  2018cites this paper
• APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice*

  2017cites this paper
• Hypertriglyceridemia on beta-cell function Effect of Hypertriglyceridemia on Beta-Cell Mass and Function in ApoC 3 Transgenic Mice

  2016cites this paper
• The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.

  2016cites this paper
• Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice*

  2016cites this paper
• Development of Antisense Drugs for Dyslipidemia

  2016cites this paper
• Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis

  2016cites this paper
• Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report.

  2016cites this paper
• New Era of Lipid-Lowering Drugs

  2016cites this paper
• Effect of hepatic insulin expression on lipid metabolism in diabetic mice

  2016cites this paper
• Gene-based therapies in lipidology: current status and future challenges

  2015cites this paper
• Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease

  2015cites this paper
• Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

  2015cites this paper
• Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention

  2015cites this paper
• Relationship of Gout and Dyslipidemia

  2015cites this paper
• Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease

  2014cites this paper
• Effects of corticosteroid treatment on high-density lipoprotein distribution and function

  2014cites this paper
• Overexpression of apolipoprotein C‐III decreases secretion of dietary triglyceride into lymph

  2014cites this paper
• Targeting APOC3 in the familial chylomicronemia syndrome.

  2014cites this paper
• Tissue-specific DNA methylation profiles regulate liver-specific expression of the APOA1/C3/A4/A5 cluster and can be manipulated with demethylating agents on intestinal cells.

  2014cites this paper
• Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma.

  2014cites this paper
• Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults.

  2013cites this paper
• Etude de la capacité d'inhibition de l'apolipoprotéine C1 sur l'activité de la protéine de transfert des esters de cholestérol chez des patients coronariens normolipidémiques et hyperlipidémiques et chez des patients diabétiques

  2013cites this paper
• Genetics of Dyslipidemia

  2012cites this paper
• Constitutive inhibition of plasma cholesteryl ester transfer protein ( CETP ) by apolipoprotein C 1 is blunted in dyslipidemic patients with coronary artery disease

  2012cites this paper
• Impact de la structure de la matière grasse sur l'absorption et le devenir métabolique des lipides et des endotoxines chez l'Homme normo-pondéré ou obèse

  2012cites this paper
• Apolipoprotein C-I binds more strongly to phospholipid/triolein/water than triolein/water interfaces: a possible model for inhibiting cholesterol ester transfer protein activity and triacylglycerol-rich lipoprotein uptake.

  2012cites this paper
• Lipids, Atherogenic Dyslipidemia, and Therapy

  2012cites this paper
• Intestinal Lipid Metabolism

  2012cites this paper
• Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease[S]

  2012cites this paper
• The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations

  2011cites this paper
• Targeting FoxO1 for hypertriglyceridemia.

  2011cites this paper
• Complexities of plasma apolipoprotein C-III metabolism1

  2011cites this paper
• Apolipoprotein CI Knock-Out Mice Display Impaired Memory Functions

  2011cites this paper
• Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII

  2011cites this paper
• A high-carbohydrate diet enhances the adverse effect of the S2 allele of APOC3 SstI polymorphism on the TG/HDL-C ratio only in young Chinese females.

  2011cites this paper
• Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins

  2010cites this paper
• Lipid Disturbances in Psoriasis: An Update

  2010cites this paper
• FoxO1 – the key for the pathogenesis and therapy of acne?

  2010cites this paper
• APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians

  2010cites this paper
• Apolipoprotein C-I genotype and serum levels of triglycerides, C-reactive protein and coronary heart disease.

  2010cites this paper
• Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses

  2010cites this paper
• ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan

  2009cites this paper
• Disorder-to-order conformational transitions in protein structure and its relationship to disease

  2009cites this paper
• Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease

  2009cites this paper
• Le point sur l’apolipoprotéine C-1: Apolipoprotein C-1: Recent data

  2009cites this paper
• Lipid dependant disorder-to-order conformational transitions in apolipoprotein CI derived peptides.

  2008cites this paper
• Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.

  2008cites this paper
• Molecular cloning and expression characterization of ApoC-I in the orange-spotted grouper

  2008cites this paper
• Plasma apolipoprotein CI protects against mortality from infection in old age.

  2008cites this paper
• Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis

  2008cites this paper
• The role of hepatocyte nuclear factor 4α (HNF4α) in the metabolic regulation of its target genes

  2008cites this paper
• Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo.

  2008cites this paper
• An ABC of apolipoprotein C‐III: a clinically useful new cardiovascular risk factor?

  2008cites this paper
• PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1

  2007cites this paper
• PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1.

  2007cites this paper
• Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractionss⃞ Published, JLR Papers in Press, February 21, 2007.

  2007cites this paper
• Severe Hypertriglyceridemia in Human APOC1 Transgenic Mice is Caused by ApoCI-Induced Inhibition of LPL

  2007cites this paper
• Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 −455T>C polymorphisms on the susceptibility to diabetic nephropathy

  2006cites this paper
• Mechanism of lipid lowering in mice expressing human apolipoprotein A5

  2005cites this paper
• Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400301-JLR200

  2005cites this paper
• Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells.

  2005cites this paper
• Influence of the Sstl polymorphism at the apolipoprotein C-Ill gene locus on the plasma low-density-lipoprotein-cholesterol response to dietary monounsaturated

  2005cites this paper
• Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins.

  2004cites this paper
• Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.

  2004cites this paper
• Influence of the -514C/T polymorphism in the promoter of the hepatic lipase gene on postprandial lipoprotein metabolism.

  2004cites this paper
• Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.

  2004cites this paper
• Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.

  2003cites this paper
• Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.

  2003cites this paper
• Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.

  2003cites this paper
• Chimeras of lipoprotein lipase and hepatic lipase : localization of the apolipoprotein C-II activation site of lipoprotein lipase

  2003cites this paper
• A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice Published, JLR Papers in Press, April 2, 2003. DOI 10.1194/jlr.M300031-JLR200

  2003cites this paper
• On the structure and function of apolipoproteins: more than a family of lipid-binding proteins.

  2003cites this paper
• A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease.

  2002cites this paper
• Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects DOI 10.1194/jlr.M200055-JLR200

  2002cites this paper
• Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase.

  2002cites this paper